earningsconfidence high
Kalaris Q1 net loss $10.9M; cash $104.9M; Phase 1b/2 TH103 screening patients
Kalaris Therapeutics, Inc.
2026-Q1 EPS reported
-$0.46
- Net loss $10.9M in Q1 2026 vs $10.2M in Q1 2025; R&D expense $7.6M (+27% YoY).
- Cash and securities $104.9M at March 31, 2026, down from $118.0M at December 31, 2025; runway into Q4 2027.
- Patient screening underway in Phase 1b/2 multiple-ascending-dose trial of TH103 for wet AMD; data expected 1H 2027.
- New manufacturing batch completed with process enhancements reducing impurities; Phase 3 initiation on track for end of 2027.
item 2.02item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.